7-122388696-A-T
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_017954.11(CADPS2):c.3051T>A(p.Asp1017Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000217 in 1,609,650 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.00014 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00023 ( 0 hom. )
Consequence
CADPS2
NM_017954.11 missense
NM_017954.11 missense
Scores
7
12
Clinical Significance
Conservation
PhyloP100: 2.06
Genes affected
CADPS2 (HGNC:16018): (calcium dependent secretion activator 2) This gene encodes a member of the calcium-dependent activator of secretion (CAPS) protein family, which are calcium binding proteins that regulate the exocytosis of synaptic and dense-core vesicles in neurons and neuroendocrine cells. Mutations in this gene may contribute to autism susceptibility. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 0 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.25799787).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
CADPS2 | NM_017954.11 | c.3051T>A | p.Asp1017Glu | missense_variant | 23/30 | ENST00000449022.7 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
CADPS2 | ENST00000449022.7 | c.3051T>A | p.Asp1017Glu | missense_variant | 23/30 | 5 | NM_017954.11 | ||
ENST00000630777.2 | n.162+34280A>T | intron_variant, non_coding_transcript_variant | 5 |
Frequencies
GnomAD3 genomes AF: 0.000138 AC: 21AN: 152084Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
21
AN:
152084
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000769 AC: 19AN: 246952Hom.: 0 AF XY: 0.0000747 AC XY: 10AN XY: 133912
GnomAD3 exomes
AF:
AC:
19
AN:
246952
Hom.:
AF XY:
AC XY:
10
AN XY:
133912
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000226 AC: 329AN: 1457566Hom.: 0 Cov.: 31 AF XY: 0.000210 AC XY: 152AN XY: 724966
GnomAD4 exome
AF:
AC:
329
AN:
1457566
Hom.:
Cov.:
31
AF XY:
AC XY:
152
AN XY:
724966
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000138 AC: 21AN: 152084Hom.: 0 Cov.: 32 AF XY: 0.0000808 AC XY: 6AN XY: 74288
GnomAD4 genome
AF:
AC:
21
AN:
152084
Hom.:
Cov.:
32
AF XY:
AC XY:
6
AN XY:
74288
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
3
ALSPAC
AF:
AC:
3
ESP6500AA
AF:
AC:
2
ESP6500EA
AF:
AC:
5
ExAC
AF:
AC:
12
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 17, 2023 | The c.3063T>A (p.D1021E) alteration is located in exon 23 (coding exon 23) of the CADPS2 gene. This alteration results from a T to A substitution at nucleotide position 3063, causing the aspartic acid (D) at amino acid position 1021 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
T;.;T;.;D
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;D;D;D;D
M_CAP
Benign
T
MetaRNN
Benign
T;T;T;T;T
MetaSVM
Benign
T
MutationAssessor
Uncertain
.;.;.;.;M
MutationTaster
Benign
D;D;D;D
PrimateAI
Uncertain
T
PROVEAN
Uncertain
.;D;.;D;D
REVEL
Benign
Sift
Benign
.;T;.;D;T
Sift4G
Benign
T;T;T;T;T
Polyphen
0.63, 0.96
.;.;.;P;D
Vest4
MutPred
0.50
.;.;.;.;Loss of ubiquitination at K1015 (P = 0.0702);
MVP
MPC
0.031
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at